The Role of Immunotherapy in Multiple Myeloma
AbstractMultiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards better understanding of normal and missing immune surveillence in myeloma have led to development of new strategies and therapies that require the engagement of the immune system. Many of these treatments are under clinical development and have already started providing encouraging results. We, for the second time in the last two decades, are about to witness another shift of the paradigm in the management of this ailment. This review will summarize the major approaches in myeloma immunotherapies. View Full-Text
Share & Cite This Article
Kocoglu, M.; Badros, A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals 2016, 9, 3.
Kocoglu M, Badros A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals. 2016; 9(1):3.Chicago/Turabian Style
Kocoglu, Mehmet; Badros, Ashraf. 2016. "The Role of Immunotherapy in Multiple Myeloma." Pharmaceuticals 9, no. 1: 3.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.